RAGE inhibition: Healthy or harmful?

Critical Care Medicine

Volumn 38, Issue 6, 2010, Pages 1487-1490

  Creagh Brown, Benedict C ^a   Quinlan, Gregory J ^a   Evans, Timothy W ^a  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Bacteria; Cytokine; HMGB1; Murine; Peritonitis; RAGE; Sepsis

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ANTIBIOTIC AGENT; CYTOKINE; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN S 100; PROTEINASE;

ACUTE LUNG INJURY; DISEASE SEVERITY; EDITORIAL; ESCHERICHIA COLI; FLUID RESUSCITATION; HUMAN; IMMUNE RESPONSE; INFECTION; INFLAMMATION; NONHUMAN; PATHOGENESIS; PERITONITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; SEPSIS; SIGNAL TRANSDUCTION;

EID: 77953046609     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181dd0837     Document Type: Editorial

References (17)

1. Bierhaus A, Schiekofer S, Schwaninger M, et al: Diabetes-associated sustained activation of the transcription factor nuclear factor-κB. Diabetes 2001; 50:2792-2808
2. Schmidt AM, Yan SD, Yan SF, et al: The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta 2000; 1498:99-111
3. Calfee CS, Ware LB, Eisner MD, et al: Plasma receptor for advanced glycation end-products and clinical outcomes in acute lung injury. Thorax 2008; 63:1083-1089
4. Wang H, Bloom O, Zhang M, et al: HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285:248-251
5. Angus DC, Yang L, Kong L, et al: Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis. Crit Care Med 2007; 35:1061-1067
6. Sunden-Cullberg J, Norrby-Teglund A, Rouhiainen A, et al: Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med 2005; 33:564-573
7. van Zoelen MA, Achouiti A, Schmidt AM, et al: Ligands of the receptor for advanced glycation end products, including high mobility group box 1, limit bacterial dissemination during Escherichia coli peritonitis. Crit Care Med 2010; 38:1414-1422
8. van Zoelen MA, Schmidt AM, Florquin S, et al: Receptor for advanced glycation end products facilitates host defense during Escherichia coli-induced abdominal sepsis in mice. J Infect Dis 2009; 200:765-773
9. Liliensiek B, Weigand MA, Bierhaus A, et al: Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest 2004; 113:1641-1650
10. Lutterloh EC, Opal SM, Pittman DD, et al: Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection. Crit Care 2007; 11: R122
11. Roger T, Froidevaux C, Le Roy D, et al: Protection from lethal gram-negative bacterial sepsis by targeting Toll-like receptor 4. Proc Natl Acad Sci USA 2009; 106:2348-2352
12. Wang H, Ward MF, Sama AE: Novel HMGB1-inhibiting therapeutic agents for experimental sepsis. Shock 2009; 32:348-357
13. Fuellen G, Foell D, Nacken W, et al: Absence of S100A12 in mouse: Implications for RAGE-S100A12 interaction. Trends Immunol 2003; 24:622-624
14. van Zoelen MA, Schouten M, de Vos AF, et al: The receptor for advanced glycation end products impairs host defense in pneumococcal pneumonia. J Immunol 2009; 182: 4349-4356
15. van Zoelen MA, van der Sluijs KF, Achouiti A, et al: Receptor for advanced glycation end products is detrimental during influenza A virus pneumonia. Virology 2009; 391: 265-273
16. Zhu S, Ashok M, Li J, et al: Spermine protects mice against lethal sepsis partly by attenuating surrogate inflammatory markers. Mol Med 2009; 15:275-282
17. Vogl T, Tenbrock K, Ludwig S, et al: Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 2007; 13:1042-1049